Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327926 | 1.00 | SCN10A (0.56) | SCN10ASCN2APOLBMCHR1CD274 | |
| SCHEMBL23327636 | 0.94 | SCN10A (0.57) | SCN10ASCN2APOLBMCHR1CD274 | |
| SCHEMBL30882097 | 0.94 | SCN10A (0.57) | SCN10ASCN2APOLBMCHR1CD274 | |
| SCHEMBL23327989 | 0.91 | SCN10A (0.60) | SCN10ASCN2APOLBPPARGKDM1A | |
| SCHEMBL23327923 | 0.90 | SCN10A (0.56) | SCN10ASCN2APOLBMCHR1CD274 | |
| SCHEMBL30882105 | 0.89 | SCN10A (0.55) | SCN10ASCN2AMCHR1CD274HTR2C | |
| SCHEMBL23327911 | 0.89 | SCN10A (0.55) | SCN10ASCN2AMCHR1CD274HTR2C | |
| SCHEMBL30882103 | 0.88 | SCN10A (0.59) | SCN10ASCN2APOLBKDM1AHDAC1 | |
| SCHEMBL23327901 | 0.88 | SCN10A (0.59) | SCN10ASCN2APOLBKDM1AHDAC1 | |
| SCHEMBL23327999 | 0.85 | SCN10A (0.61) | SCN10ASCN2APOLBKDM1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | claimed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | claimed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | SCN10A 8/4885SCN2A 3/4885POLB 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.